The filing was just an amendment that went into some of the details for the deal with Lee's Pharma of Hong Kong. Pretty much boiler plate stuff. Only tidbit was that it is dislcosed that 6 months after the deal signed, a "Joint development Committee" (Lee's and RGRX) will meet or agree on a development path for the clinical trial(s) that Lee's has to do. That 6 month deadline was Jan 19. So you can assume there has been recent interaction between Lee's & RGRX..and probably Sigma Tau. Still, don't get hopes up. Initiation of a Hong kong/China trial could be a ways off. And RGRX is out of money again in 60 days or so. I don't know how long ST, BOD and McNAy will keep putting in band aid fundings. Doesn't look that rosy here.
This Amendment No. 1 amends the Registrant's Quarterly Report on Form 10-Q for
the quarterly period ended September 30, 2012 (the "Report"), originally filed
with the U.S. Securities and Exchange Commission (the "SEC") on November 14,
2012. The Registrant is filing this Amendment No. 1 solely to update Exhibit
10.1 in response to comments from the staff of the SEC.